Chinese health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
A woman with COVID symptoms receives intravenous drip while using a ventilator at the emergency ward of a hospital in Fuyang in central China's Anhui province on Jan. 4, 2023. China's healthcare authorities declined to include Pfizer's COVID-treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
TAIPEI, Taiwan — Chinese health care authorities declined to include Pfizer’s COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. Paxlovid, an oral medicine developed by New York-based drugmaker Pfizer, has been widely sought after in China since the country began
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Chinese Traveling for Lunar New Year as COVID SurgesWith COVID-19 cases already increasing in China, millions of people are traveling home to visit relatives during the Lunar New Year, which began Saturday.
Lire la suite »
China says talks to include Paxlovid in state health insurance failChina's Health Security Administration said on Sunday that talks to include Pfizer's Paxlovid in the latest drug list for basic state health insurance did not succeed.
Lire la suite »
China says talks to include Paxlovid in its insurance drug list failChina will not include Pfizer Inc's Paxlovid in an update to its list of medicines covered by basic medical insurance schemes as the U.S. firm quoted a high price for the COVID-19 drug, China's Healthcare Security Administration (NHSA) said on Sunday.
Lire la suite »
What’s Next At The Chinese Box Office As Covid & Politics Prove An Unpredictable MixReading the tea leaves with regard to China in 2023 is even more difficult than usual. The country’s about-face on its longstanding zero-Covid policy has implications from geopolitics to econ…
Lire la suite »
Chinese rush to renew passports as COVID border curbs liftedPeople joined long queues outside immigration offices in Beijing on Monday, eager to renew their passports after China dropped COVID border controls that had largely prevented its 1.4 billion residents from travelling for three years.
Lire la suite »